Status:
COMPLETED
Telehealth-enhanced Hybrid Cardiac Rehabilitation Among Acute Coronary Syndrome Survivors
Lead Sponsor:
Columbia University
Collaborating Sponsors:
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
Conditions:
Acute Coronary Syndrome
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study investigates the feasibility of conducting a randomized controlled trial of telehealth-enhanced hybrid cardiac rehabilitation (THCR) compared with traditional cardiac rehabilitation (CR) am...
Detailed Description
Cardiac Rehabilitation (CR) is a Class I, Level A secondary prevention program that significantly reduces reinfarction and mortality rates in acute coronary syndrome (ACS) survivors. Yet, fewer than 3...
Eligibility Criteria
Inclusion
- over the age of 18;
- can speak and read English or Spanish;
- confirmed ACS based on ICD-10 codes; and
- had their index event within the past 12 months.
Exclusion
- severe disabling chronic medical and/or psychiatric comorbidities determined on a case-by-case basis that prevent safe or adequate participation;
- high-risk for adverse exercise-related cardiovascular events according to the AACVPR risk stratification criteria;
- participated in \>1 CR program session;
- deemed unable to comply with the protocol (either self-selected or indicated during screening that s/he could not complete all requested tasks). This includes, but is not limited to, patients with a level of cognitive impairment indicative of dementia, patients with current alcohol or substance abuse, patients with a significant movement or balance disorder that interferes with walking, patients with impaired circulation or poor perfusion that may impede pulse oximeter readings, and patients with severe mental illness (e.g., schizophrenia);
- home-based environment deemed incompatible with the protocol and/or that prevent safe or adequate participation (either self-selected or indicated during screening/onboarding process); and
- unavailable for follow-up for reasons such as terminal illness and imminent plans to leave the United States (as we have migrant or mobile patients due to their citizenship and work issues).
Key Trial Info
Start Date :
March 11 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2023
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05328375
Start Date
March 11 2022
End Date
May 1 2023
Last Update
October 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Irving Medical Center
New York, New York, United States, 10032